(Reuters) -AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to the United States, the Times reported on Tuesday, citing multiple sources. Any such move would be a major blow to the UK stock market, which has seen a string of delistings and missed out on some major initial public offerings in recent months. It would also appeal to President Donald Trump's hopes of drawing investment to the United States, even as his trade policy has created uncertainty for global companies. AstraZeneca, which has a market value of about 156 billion pounds ($213 billion), declined to comment. Its U.S. plans include a $3.5 billion investment in domestic manufacturing by the end of 2026.

Source: The Times July 01, 2025 15:29 UTC